An emulsion skin "Lokoid Krelo" is applied at states when there is a response to treatment by corticosteroids (eczema, dermatitis, psoriasis). Topical corticosteroids in general are not shown for treatment of psoriasis, but can be acceptable, except for widespread blyashechny psoriasis, on condition of respect for precautions.

Structure

Active ingredient - a hydrocortisone 17 butyrate (1 g of an emulsion contains 1 mg of a hydrocortisone 17 butyrates).

Excipients: cetostearyl alcohol, a macrogoal cetostearyl air, paraffin white soft, paraffin, oil to a borazha, propylene glycol, butyl hydroxytoluene (E 321), propilparagidroksibenzoat (E 216), butylparahydroxybenzoate, sodium citrate, citric acid waterless, the water purified.

Contraindication

except for treatment cases in combination with the appropriate chemotherapeutic means:

• injury of skin (wound), caused by bacterial infections (for example a pyoderma, syphilitic or tubercular defeats), viral infections (for example chicken pox, the herpes simplex surrounding herpes, a wart ordinary, a wart a flat, peaked condyloma, a contagious mollusk); the infections caused by fungi and yeast; parasitic infections (for example mange);
• skin cankers;
• side reactions caused by corticosteroids (for example perioral dermatitis, striya);
• ichthyosis, juvenile bottom dermatosis, vulgar eels, rozatsea, fragility of vessels of skin, skin atrophy;
• allergic reactions of hypersensitivity to components of medicine or corticosteroids (the last arise seldom);
• a new growth of skin.

Route of administration

For skin application.

in a small amount with a thin uniform layer on affected areas no more than 2 times a day.

This form of production of medicine allows to apply it as at defeats which are followed by peeling, and the becoming wet defeats.

General course dose should not exceed 30-60 g of medicine a week.

to Adults and patients of advanced age are applied by identical doses as there are no clinical proofs demonstrating that patients of advanced age need the special mode of dosing.

Feature of application

Pregnant women

Data on application of a hydrocortisone butyrate to pregnant women are absent or are limited. Results of researches on laboratory animals indicate reproductive toxicity of medicine. Corticosteroids get through a placenta. At system application of high doses of corticosteroids it was reported about influence on a fruit or the newborn child (fruit growth inhibition, adrenocortical suppression). Despite small amount of information on application of corticosteroids on skin to pregnant women, considering limited system absorption of medicines of this group, application of corticosteroids of weak and moderate action (class 1 and class 2), such as hydrocortisone, during the short spans and on limited sites of skin is possible. Above-mentioned effects cannot be excluded at prolonged use or when drawing on big sites of skin. It can be done only in the presence of special indications.

Hydrocortisone butyrates/metabolites get into breast milk, however at use of medicine in therapeutic doses of impact on the newborns/babies who are on breastfeeding it is not expected. Women can use medicament during feeding by a breast only in the conditions of short-term treatment and drawing on small sites of skin. At long-term treatment or drawing on big sites of the affected skin it is necessary to stop feeding by a breast.

If it is possible

, it is necessary to avoid long-term treatment. Aged from 3 months up to one year - if it is possible, the period of treatment has to last at most 7 days.

Drivers

Are absent data on influence of medicine on ability to steer motor transport or other mechanisms, emergence of influence is not expected.

At excessive application under an occlusive bandage the emergence of suppression of adrenal glands is possible

. Special medical procedures or antidote do not exist. At emergence of any side effects the treatment should be stopped and carried out symptomatic treatment.

Side effects

from skin and hypodermic cellulose: seldom (> 1/10000, <1/1000) - dermatitis, eczema, striya, contact dermatitis; contact allergy, pustular acne; skin atrophy, often irreversible, followed by thinning of epidermis, teleangiectasias, purpura and extensions; depigmentation, hypertrichosis; rozatseapodibny and perioral dermatitis which is followed or not followed by a skin atrophy; "effect of a ricochet" that can result in steroid dependence; the slowed-down healing of wounds; skin infection, reddening, irritation, burning, rash, itch, xeroderma, folliculitis, heat rash, acne, maceration.

Endocrine violations: seldom (> 1/10000, <1/1000) - adrenocortical suppression, Cushing's syndrome, a hyperglycemia, a glucosuria, a growth inhibition and intracranial hypertensia.

from organs of sight: very seldom (<1/10000, including separate messages) - increase in intraocular pressure and risk of developing of a cataract (at systematic hit of medicine on a conjunctiva).

from the immune system: very seldom (<1/10000, including separate messages) - reactions of hypersensitivity.

to Store

in original packing at a temperature not above 25 °C, out of children's reach.

Expiration date - 2 years.